Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$12.75
-1.9%
$13.26
$1.27
$15.85
$20.88M1.212,149 shs1,741 shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$10.21
-0.2%
$9.22
$4.80
$18.13
$391.54M1.49693,493 shs536,023 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$9.98
-0.3%
$10.53
$6.65
$12.61
$680.99M0.026,105 shs5,740 shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$19.83
+7.2%
$17.13
$11.51
$25.50
$967.37M-2.8270,815 shs58,015 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-1.92%-2.49%-4.76%+2.82%+858.65%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%0.00%0.00%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-0.20%+0.39%+1.79%+80.71%-33.05%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-0.35%-3.90%-15.47%+23.91%+17.22%
Pharvaris N.V. stock logo
PHVS
Pharvaris
+7.19%+5.70%+9.44%+65.25%+11.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1.1444 of 5 stars
0.03.00.00.02.91.70.6
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.3524 of 5 stars
4.12.00.00.02.03.30.6
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.003 of 5 stars
3.55.00.00.02.60.00.6
Pharvaris N.V. stock logo
PHVS
Pharvaris
1.5407 of 5 stars
3.51.00.00.02.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00
N/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.14
Hold$15.8655.31% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00200.75% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
3.00
Buy$36.2082.55% Upside

Current Analyst Ratings Breakdown

Latest PHVS, ITOS, FNCH, GRCL, and PHAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
6/5/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$27.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$10.00 ➝ $12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.00
5/14/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$60K12,415.83N/AN/A$2.95 per share3.47
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M11.16N/AN/A$16.16 per share0.63
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$320.71M2.12$0.07 per share135.04$3.25 per share3.07
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$5.54 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.20N/A332.50N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)

Latest PHVS, ITOS, FNCH, GRCL, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.15N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.80-$0.89-$0.09-$0.89N/AN/A
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
4/28/2025Q1 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.02
7.73
7.73
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.13
14.13
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.10
11.10

Institutional Ownership

CompanyInstitutional Ownership
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
31472.68 million52.33 millionOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.27 million33.49 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.03 million66.62 millionNot Optionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable

Recent News About These Companies

Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) PT at $36.20
Pharvaris Announces Annual Meeting of Shareholders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$12.75 -0.25 (-1.92%)
As of 07/10/2025 01:49 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Gracell Biotechnologies stock logo

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$10.21 -0.02 (-0.20%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$10.22 +0.00 (+0.05%)
As of 07/10/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$9.98 -0.04 (-0.35%)
Closing price 07/10/2025 03:51 PM Eastern
Extended Trading
$10.10 +0.13 (+1.30%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$19.83 +1.33 (+7.19%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$19.96 +0.14 (+0.68%)
As of 07/10/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.